509 related articles for article (PubMed ID: 32539093)
1. Monoclonal Antibodies for Prevention and Treatment of COVID-19.
Marovich M; Mascola JR; Cohen MS
JAMA; 2020 Jul; 324(2):131-132. PubMed ID: 32539093
[No Abstract] [Full Text] [Related]
2. COVID-19 Antibody Trials Have Begun.
Abbasi J
JAMA; 2020 Jul; 324(2):128. PubMed ID: 32662848
[No Abstract] [Full Text] [Related]
3. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses.
Jiang S; Hillyer C; Du L
Trends Immunol; 2020 May; 41(5):355-359. PubMed ID: 32249063
[TBL] [Abstract][Full Text] [Related]
4. Nanobodies: Prospects of Expanding the Gamut of Neutralizing Antibodies Against the Novel Coronavirus, SARS-CoV-2.
Konwarh R
Front Immunol; 2020; 11():1531. PubMed ID: 32655584
[No Abstract] [Full Text] [Related]
5. COVID-19 and SARS Coronavirus 2: Antibodies for the Immediate Rescue and Recovery Phase.
Halstead SB; Akkina R
Front Immunol; 2020; 11():1196. PubMed ID: 32574267
[No Abstract] [Full Text] [Related]
6. Audio Interview: Approaches to Covid-19 Vaccines and Antivirals.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2020 Apr; 382(16):e58. PubMed ID: 32320592
[No Abstract] [Full Text] [Related]
7. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model.
Rogers TF; Zhao F; Huang D; Beutler N; Burns A; He WT; Limbo O; Smith C; Song G; Woehl J; Yang L; Abbott RK; Callaghan S; Garcia E; Hurtado J; Parren M; Peng L; Ramirez S; Ricketts J; Ricciardi MJ; Rawlings SA; Wu NC; Yuan M; Smith DM; Nemazee D; Teijaro JR; Voss JE; Wilson IA; Andrabi R; Briney B; Landais E; Sok D; Jardine JG; Burton DR
Science; 2020 Aug; 369(6506):956-963. PubMed ID: 32540903
[TBL] [Abstract][Full Text] [Related]
8. Antibodies may curb pandemic before vaccines.
Cohen J
Science; 2020 Aug; 369(6505):752-753. PubMed ID: 32792373
[No Abstract] [Full Text] [Related]
9. Coronavirus vaccines get a biotech boost.
Dance A
Nature; 2020 Jul; 583(7817):647-649. PubMed ID: 32694847
[No Abstract] [Full Text] [Related]
10. Vaccine designers take first shots at COVID-19.
Cohen J
Science; 2020 Apr; 368(6486):14-16. PubMed ID: 32241928
[No Abstract] [Full Text] [Related]
11. Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview.
Ali MG; Zhang Z; Gao Q; Pan M; Rowan EG; Zhang J
Immunol Res; 2020 Dec; 68(6):325-339. PubMed ID: 33161557
[TBL] [Abstract][Full Text] [Related]
12. What Would Jenner and Pasteur Have Done About COVID-19 Coronavirus? The Urges of a Vaccinologist.
Palatnik-de-Sousa CB
Front Immunol; 2020; 11():2173. PubMed ID: 32983183
[No Abstract] [Full Text] [Related]
13. Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection.
Wan J; Xing S; Ding L; Wang Y; Gu C; Wu Y; Rong B; Li C; Wang S; Chen K; He C; Zhu D; Yuan S; Qiu C; Zhao C; Nie L; Gao Z; Jiao J; Zhang X; Wang X; Ying T; Wang H; Xie Y; Lu Y; Xu J; Lan F
Cell Rep; 2020 Jul; 32(3):107918. PubMed ID: 32668215
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines.
Salvatori G; Luberto L; Maffei M; Aurisicchio L; Roscilli G; Palombo F; Marra E
J Transl Med; 2020 Jun; 18(1):222. PubMed ID: 32493510
[TBL] [Abstract][Full Text] [Related]
15. Passive antibody therapy in COVID-19.
Abraham J
Nat Rev Immunol; 2020 Jul; 20(7):401-403. PubMed ID: 32533109
[TBL] [Abstract][Full Text] [Related]
16. Impact of glycoscience in fighting Covid-19.
Adamo R; Sonnino S
Glycoconj J; 2020 Aug; 37(4):511-512. PubMed ID: 32504168
[No Abstract] [Full Text] [Related]
17. Vaccines, convalescent plasma, and monoclonal antibodies for covid-19.
Sewell HF; Agius RM; Kendrick D; Stewart M
BMJ; 2020 Jul; 370():m2722. PubMed ID: 32646867
[No Abstract] [Full Text] [Related]
18. Bridging the Gap at Warp Speed - Delivering Options for Preventing and Treating Covid-19.
Slaoui M; Greene SE; Woodcock J
N Engl J Med; 2020 Nov; 383(20):1899-1901. PubMed ID: 32931679
[No Abstract] [Full Text] [Related]
19. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W
Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838
[TBL] [Abstract][Full Text] [Related]
20. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability.
Brouwer PJM; Caniels TG; van der Straten K; Snitselaar JL; Aldon Y; Bangaru S; Torres JL; Okba NMA; Claireaux M; Kerster G; Bentlage AEH; van Haaren MM; Guerra D; Burger JA; Schermer EE; Verheul KD; van der Velde N; van der Kooi A; van Schooten J; van Breemen MJ; Bijl TPL; Sliepen K; Aartse A; Derking R; Bontjer I; Kootstra NA; Wiersinga WJ; Vidarsson G; Haagmans BL; Ward AB; de Bree GJ; Sanders RW; van Gils MJ
Science; 2020 Aug; 369(6504):643-650. PubMed ID: 32540902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
